Erin Simpson, NP
Family · Ringgold, GANPI 1700299419
Payments from drug & device makers
Across 233 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$549
- AstraZeneca$456
- Lilly USA, LLC$393
- Sanofi-aventis U.S. LLC$329
- Pfizer$279
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,083 |
| GSK | 29 | $549 |
| AstraZeneca | 14 | $456 |
| Lilly USA, LLC | 22 | $393 |
| Sanofi-aventis U.S. LLC | 12 | $329 |
| Pfizer | 18 | $279 |
| Axsome Therapeutics, Inc. | 9 | $204 |
| Novo Nordisk | 10 | $203 |
| Bayer | 7 | $142 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $128 |
| Dexcom, Inc. | 2 | $107 |
| Sumitomo Pharma America, Inc. | 3 | $86 |
| Boehringer Ingelheim | 3 | $64 |
| Amarin Pharma, Inc. | 3 | $64 |
| Amgen | 4 | $53 |
| Shield Therapeutics Inc | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Inspire Medical Systems, Inc. | 2 | $29 |
| Antares Pharma, Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Abbott | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Medtronic | 1 | $16 |
| Merck | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Smith+Nephew | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- Auvelity$125
- SOLIQUA 100/33$122
How this compares
$4,619 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 166 | $182,630 |
| EliquisApixaban | 43 | $42,738 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $40,046 |
| FarxigaDapagliflozin Propanediol | 49 | $37,933 |
| UbrelvyUbrogepant | 15 | $26,925 |
| JardianceEmpagliflozin | 31 | $22,681 |
| OzempicSemaglutide | 15 | $21,066 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $14,078 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $12,410 |
| XareltoRivaroxaban | 19 | $10,808 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,893 |
| Rosuvastatin Calcium | 188 | $2,435 |
| Losartan Potassium | 193 | $2,087 |
| Omeprazole | 155 | $1,619 |
| Levothyroxine Sodium | 197 | $1,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $393 | $182,630166 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $456 | $44,82660 claims |
| PfizerEliquis | $279 | $42,73843 claims |
| GSKTrelegy Ellipta | $549 | $40,04641 claims |
| AbbVieUbrelvy | $1,083 | $26,92515 claims |
| Boehringer IngelheimJardiance | $64 | $22,68131 claims |
| Novo NordiskOzempic | $203 | $21,06615 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $329 | $12,41014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Ringgold
- Amanda SmidtRinggold$14K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.